YONKERS, New York, Sept. 04, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of...
Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Telecoms, Industrials and Utilities sectors led shares higher. At the close in NYSE, the Dow...
Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Consumer Services, Oil & Gas and Telecoms sectors led shares higher. At the close in NYSE, the...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Strong Sell||Sell||Strong Sell|
|Technical Indicators||Strong Sell||Strong Sell||Sell||Strong Sell||Strong Sell|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Falling Three Methods||1H||Current|
|Bullish doji Star||1M||1||Sep 19|
|Engulfing Bearish||1W||3||Sep 22, 2019|
|Upside Gap Three Methods||1W||3||Sep 22, 2019|
|Can Fite Biopharma ADR||2.3200||2.4354||2.1409||+0.1532||+7.07%||89.20K||16/10|
|Bank of America||30.17||30.72||30.15||+0.44||+1.48%||87.48M||16/10|
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.